COYA THERAPEUTICS, INC. COMMON STOCK

NASDAQ: COYA (Coya Therapeutics, Inc.)

Last update: 02 Dec, 10:28PM

5.98

-0.26 (-4.17%)

Previous Close 6.24
Open 6.30
Volume 192,175
Avg. Volume (3M) 186,575
Market Cap 125,128,248
Price / Sales 27.16
Price / Book 4.99
52 Weeks Range
4.65 (-22%) — 8.29 (38%)
Earnings Date 12 Nov 2025
Operating Margin (TTM) -2,976.89%
Diluted EPS (TTM) -1.07
Quarterly Revenue Growth (YOY) 103.30%
Current Ratio (MRQ) 8.84
Operating Cash Flow (TTM) -15.26 M
Levered Free Cash Flow (TTM) -10.29 M
Return on Assets (TTM) -32.06%
Return on Equity (TTM) -52.11%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bullish Mixed
Biotechnology (Global) Bullish Mixed
Stock Coya Therapeutics, Inc. Bearish Mixed

AIStockmoo Score

1.4
Analyst Consensus 4.0
Insider Activity NA
Price Volatility 2.0
Technical Moving Averages 0.0
Technical Oscillators -0.5
Average 1.38

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
COYA 125 M - - 4.99
IONS 13 B - - 21.49
RNA 11 B - - 5.70
ARWR 10 B - - 17.90
NUVL 8 B - - 9.65
CDTX 7 B - - 16.47

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 7.02%
% Held by Institutions 28.08%
52 Weeks Range
4.65 (-22%) — 8.29 (38%)
Price Target Range
14.00 (134%) — 16.00 (167%)
High 16.00 (BTIG, 167.56%) Buy
Median 15.00 (150.84%)
Low 14.00 (Chardan Capital, 134.11%) Buy
Average 15.00 (150.84%)
Total 3 Buy
Avg. Price @ Call 5.95
Firm Date Target Price Call Price @ Call
D. Boral Capital 09 Dec 2025 15.00 (150.84%) Buy 6.02
12 Nov 2025 15.00 (150.84%) Buy 6.09
Chardan Capital 14 Nov 2025 14.00 (134.11%) Buy 5.87
17 Sep 2025 14.00 (134.11%) Buy 5.41
BTIG 13 Nov 2025 16.00 (167.56%) Buy 5.96
30 Sep 2025 15.00 (150.84%) Buy 5.70

No data within this time range.

Date Type Details
25 Nov 2025 Announcement Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
12 Nov 2025 Announcement Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
04 Nov 2025 Announcement Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
27 Oct 2025 Announcement Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
24 Oct 2025 Announcement Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
23 Oct 2025 Announcement Coya Therapeutics Announces Proposed Public Offering of Common Stock
07 Oct 2025 Announcement Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function
29 Sep 2025 Announcement Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia
22 Sep 2025 Announcement Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis
16 Sep 2025 Announcement Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria